12 results about "Increased Bone Density" patented technology

This invention relates to a nutritional composition for promoting bone development and its applications. The invention provides applications of the nutritional composition or preparations comprising said nutritional composition, including: (1) preparing food products; (2) preparing health products for promoting bone development, increasing height, and / or improving bone density; (3) preparing drugs or drug compositions for promoting bone development, increasing height, increasing bone density, treating or preventing osteoporosis, and / or treating or preventing skeletal dysplasia; and (4) promoting bone development, increasing height, and / or improving bone density for non-therapeutic purposes; wherein said nutritional composition comprises medium- and long-chain triglycerides (MLCT) and 1,3-diunsaturated fatty acid-2-palmitoyltriglycerides (UPU).

This application provides a collagen peptide for increasing bone density and a method for preparing the same. The method includes the following steps: S1: dispersing bone gelatin in water to obtain a bone gelatin solution; S2: adding 0.1-1 mol / L acidic pH adjuster to the bone gelatin solution at a rate of 1-10 mL / min until the turbidity of the system increases by 10%-20% compared to the initial bone gelatin solution, then stopping the addition, allowing it to stand for 10-30 min, and filtering to obtain a bone gelatin supernatant; S3: adding an endopeptide to the bone gelatin supernatant to obtain an enzymatic hydrolysate; S4: post-processing and drying the enzymatic hydrolysate to obtain collagen peptides. This method can increase the mass ratio of low molecular weight peptides in the obtained collagen peptides, resulting in a composition of collagen peptides more suitable for bone metabolism and utilization to increase bone density.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

This invention discloses a Hu sheep active peptide complex and its application in bone health care. Using healthy Hu sheep bones as raw material, collagen is extracted after defatting and decalcification. This collagen is then enzymatically hydrolyzed with trypsin and alkaline protease, followed by ultrafiltration, desalting, and freeze-drying to obtain Hu sheep bone collagen peptides. These collagen peptides are mixed with pharmaceutical excipients, calcium source compounds, chondroprotective agents, and fat-soluble vitamins. An ethanol-water binder solution containing palmitoyl aspartate diethyl ester and hesperidin-3-O-glucoside is added, and the mixture is granulated, dried, sized, and pressed to obtain the active peptide complex. This complex, through the synergistic effect of its components, can significantly promote osteoblast proliferation and inhibit apoptosis, effectively increasing bone density in osteoporosis model animals. It also exhibits excellent biocompatibility and no cytotoxicity, solving the problems of limited function, insufficient preparation efficiency, and instability of existing single active peptides. This makes it suitable for the development and application of bone health-related nutritional supplements.

The application discloses a hydrolyzed egg yolk peptide for improving bone growth and bone density as well as preparation and application thereof. The hydrolyzed egg yolk peptide is a tetrapeptide SFPA with an amino acid sequence of Ser-Phe-Pro-Ala. The hydrolyzed egg yolk peptide can be prepared by enzymatic hydrolysis of defatted egg yolk powder. The tetrapeptide SFPA is a food-derived bioactive peptide. It is verified by a zebrafish model that the tetrapeptide SFPA has a significant effect of promoting longitudinal bone growth and increasing bone density. For a normally growing and developing zebrafish, the body length of the zebrafish is increased by 3.4% after intervention of the hydrolyzed egg yolk peptide. For a slow-growing zebrafish, the body length of the zebrafish is increased by 3.9% and the bone density is increased by 19.6% after intervention of the hydrolyzed egg yolk peptide. The hydrolyzed egg yolk peptide can be used for preparing a product for improving bone density and / or for improving bone growth.

This invention provides a probiotic, a probiotic composition, and their applications, all possessing the functions of calcium ion enrichment and vitamin K synthesis. This invention belongs to the field of microbial technology. The probiotic provided by this invention is *Lactobacillus bulgaricus* subsp. Lactobacillus delbrueckii subsp. bulgaricus NWP-101 or Pyrococcus lactis ( Pediococcus acidilactici NWP-299 has the advantages of efficient calcium enrichment, high vitamin K production and excellent probiotic properties. It can be used to prepare probiotic preparations, functional foods, health foods or dietary supplements to prevent or improve osteoporosis and increase bone density.

This application relates to the field of biotechnology, and particularly to collagen peptides that promote osteoblast proliferation and differentiation and increase bone density, as well as their preparation methods and applications. The method includes (A) soaking coarsely shaped cartilage in an alkaline solution, followed by washing the soaked cartilage; (B) removing grease from the cartilage; (C) washing the grease-removed cartilage with an acid solution; (D) subjecting the acid-washed cartilage to high-pressure heat treatment using microwave heating; (E) stepwise enzymatic hydrolysis, including first hydrolyzing the cartilage with a protease, followed by further hydrolysis with chondroitin sulfate ABC enzyme; and (F) purifying the enzyme-inactivated hydrolysate by alcohol precipitation. The product obtained by this method exhibits good acid resistance and is rich in small molecule chondroitin sulfate.

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a zeolite composite composition for improving osteoporosis and a preparation method thereof. The preparation method of the zeolite composite composition for improving osteoporosis is as follows: clinoptilolite is taken, water is added, centrifugal sedimentation is carried out, activation is carried out, and crushing is carried out to obtain zeolite powder; radix cibotii, luffa, heavy yang wood, chicken tendon, poria cocos, astragalus root and licorice are weighed, crushed, sieved, soaked in water, decocted, filtered, and the first filtrate is collected; the first filter residue is soaked in water, decocted, filtered, and the second filtrate is collected; the two filtrates are combined, concentrated into extract, dried and crushed to obtain extract powder; the extract powder and the zeolite powder are uniformly mixed, and excipients are added to prepare tablets. The zeolite composite composition has reasonable compatibility, and the drugs jointly play the effects of tonifying kidney and essence, invigorating spleen and qi, and promoting blood circulation to remove blood stasis, and the zeolite powder can regulate bone metabolism, inhibit bone absorption, promote bone formation, and further increase bone density, so that osteoporosis can be effectively treated.

The application provides application of uterine mesenchymal stem cell exosomes in preparation of drugs for preventing and treating osteoporosis, and belongs to the technical field of biological medicine. The uterine mesenchymal stem cell-derived exosomes provided by the application have extremely low immunogenicity and good biological safety, avoid the immune rejection and adverse reactions possibly caused by traditional drugs or cell therapy, can be effectively targeted to the skeletal system, especially the diseased bone marrow microenvironment, and realize precise drug delivery; the exosomes not only can effectively increase bone density and improve bone microstructure, but also can improve the biomechanical strength of the skeleton, significantly reduce the risk of fracture; in addition, the preparation process is mature and stable, and as a natural cell-free therapeutic product, the exosomes avoid the ethical and safety concerns related to live cell transplantation, and provide a new strategy with great clinical application potential for the prevention and treatment of osteoporosis.

The present invention relates to a novel lappaconitine derivative and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a medical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cells into preosteoblasts, and increases bone density when administered to an osteoporosis animal model, and induces osteogenesis, and thus can be effectively used for preventing, alleviating, or treating bone-related diseases such as osteoporosis.

This invention relates to the field of microbial technology, specifically to a *Lactobacillus rhamnosus* JYLR-219 strain for preventing osteoporosis, its inoculum, and its application. Lactobacillus rhamnosus Lactobacillus rhamnosus JYLR-219 was deposited on July 8, 2019, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC NO.18097. This Lactobacillus rhamnosus JYLR-219 can be used to prepare products for the prevention of osteoporosis. Lactobacillus rhamnosus JYLR-219 has a strong gastrointestinal survival rate and intestinal colonization ability. It can increase bone density by increasing osteoblast density and decreasing osteoclast density, thereby preventing osteoporosis. This invention has the advantages of being safe, effective, and without side effects.

The application discloses a kind of bovine collagen peptide for increasing bone density and a preparation method thereof, and relates to the technical field of enzyme processing preparation of protein peptide.The application relates to the application of bovine collagen peptide in the field of composition.The composition containing bovine collagen peptide is prepared from the following components in mass fraction:bovine collagen peptide 25-45 parts, calcium citrate 12-28 parts, vitamin D 0.0002-0.0004 parts, extract of rhizoma drynariae 6-14 parts, extract of astragalus 4-9 parts, auxiliary materials 12-38 parts, and zoledronate derivative 0.01-0.05 parts.The application breaks through the limitation of single component and poor synergistic effect in the prior art, and forms a multi-dimensional action system of "inhibiting bone resorption, promoting bone formation and supplementing matrix" by matching bovine collagen peptide, calcium citrate, traditional Chinese medicine extract and modified zoledronate derivative, so that the effect of improving bone density is improved.